A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients

Inclusion Criteria: * Fluent in English able to understand and provide informed consent * End stage renal disease listed for primary solitary kidney transplant * Willing to participate in the study and comply with study requirements * Female participants must agree to use 2 different birth control methods Exclusion Criteria: * History of previous organ, tissue or cell transplant * Known sensitivity to Sirolimus, Everolimus, Tacrolimus or MMF * Previous chronic use of systemic glucocorticoids or other immunosuppression, or biologic immunomodulators * Significant or active infection: HIV, Hepatitis B and C * Active cancer or history of cancer within 3 years of screening * Participation in other study that involved investigational drug or regimens in the preceding 12 months * History of delayed or abnormal wound healing * Delayed graft function * Chronic illness or prior treatment which, in the opinion of the investigator, precludes study participation * Pregnant or breastfeeding or refusal to us birth control * Inability or unwillingness to comply with study protocol or procedures * Chronic use of anticoagulants * Blood transfusion 3 months prior to transplant * History of non-compliance